Johnson & Johnson to start human safety trial for Covid-19 vaccine

Elias Hubbard
August 2, 2020

ANTHONY Fauci, the United States' top infectious disease official, raised concerns yesterday regarding the safety of Covid-19 vaccines under development by China and Russian Federation.

Shattock told AP he is optimistic the vaccine that his team developed will work, but they must first wait for the scientific data that they will gather from the trial. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.

Researchers and pharmaceutical companies in other countries including the US, UK, Japan and China are also racing to develop vaccines.

Barouch and colleagues conducted a study in 52 NHPs, immunizing 32 adult rhesus macaques with a single dose of one of seven different versions of the Ad26-based vaccine, and giving 20 animals sham vaccines as placebo controls. US -based Moderna is one of the companies furthest along in vaccine development.

The minister, who did not give details about the vaccine to be used, said doctors and teachers would be the first to be vaccinated.

More than 100 possible vaccines are being developed around the world to try to stop the Covid-19 pandemic.

Earlier study, which was supported by the United States government, showed that all vaccinated monkeys that were protected from the COVID-19. The last phase of the vaccine developed so far is underway.

Stoffels said J&J would decide in the next few weeks whether it will include pregnant women in its large Phase 3 late-stage trial for a COVID-19 vaccine due to start in September. The cells then use the spike gene to replicate the coronavirus proteins and protect themselves from the virus. "It really depends on how strong the immune response needs to be to provide protection".

And within than two weeks from now, Russian Federation may approve the desperately needed coronavirus vaccine.

Inovio, a company developing a DNA-based vaccine, announced Thursday that monkeys challenged four months after vaccination had a reduced load of the virus in their nose and lungs. At the forefront of this is the vaccine of Oxford University (oxford corona vaccine). "We don't necessarily have to finish the Phase 3 trials".

Shattock, who is leading the research on the vaccine at Imperial, said that "We are still doing research on it".

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER